Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02991898 · ClinicalTrials.gov registry record · Phase 2
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02991898 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 3 participants.
The verdict
NCT02991898, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a single center pilot study of a non-myeloablative umbilical cord blood transplant for the treatment of a hematological malignancy with a single infusion of T regulatory (Treg) given shortly after UCB transplantation.
Interventions
- BIOLOGICAL Infusion of Treg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-02-16 |
| Est. Completion | 2019-06-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02991898
The ClinicalTrials.gov registry entry for NCT02991898 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Infusion of Treg is the first listed.
NCT02991898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02991898 about?
NCT02991898 is a clinical study titled "Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies". This is a single center pilot study of a non-myeloablative umbilical cord blood transplant for the treatment of a hematological malignancy with a single infusion of T regulatory (Treg) given shortly after UCB transplantation.
What is the current status of trial NCT02991898?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2017-02-16. Estimated completion is 2019-06-20.
What interventions are being tested in trial NCT02991898?
The interventions under investigation include: Infusion of Treg (BIOLOGICAL).
Who is sponsoring clinical trial NCT02991898?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.